ArticleCancer communications (London, England)2018

First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution's clinical practice experience.

Xiangyang Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.